Jun J. Yang
- Hematology top 0.5%
- Acute Myeloid Leukemia Research 23
- Chronic Myeloid Leukemia Treatments 12
-
- Acute Lymphoblastic Leukemia research 95
-
- Childhood Cancer Survivors' Quality of Life 51
- Sensory Systems top 1%
- Speech and Hearing top 1%
-
- Epigenetics and DNA Methylation 16
- RNA modifications and cancer 10
- Biochemical and Molecular Research 9
-
- Immune Cell Function and Interaction 13
Jun J. Yang
175 papers receiving 6.9k citations
Hit Papers
Peers
Comparison fields: 5 of 147
- Hematology 1.3k
- Public Health, Environmental and Occupational Health 3.0k
- Pediatrics, Perinatology and Child Health 1.9k
- Sensory Systems 329
- Speech and Hearing 311
Countries citing papers authored by Jun J. Yang
This map shows the geographic impact of Jun J. Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jun J. Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jun J. Yang more than expected).
Fields of papers citing papers by Jun J. Yang
This network shows the impact of papers produced by Jun J. Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jun J. Yang. The network helps show where Jun J. Yang may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Jun J. Yang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 2 | |
| 2 | 2024 | 0 | |
| 3 | 2023 | 58 | |
| 4 | 2023 | 2 | |
| 5 | 2023 | 20 | |
| 6 | 2023 | 4 | |
| 7 | 2023 | 9 | |
| 8 | 2022 | 8 | |
| 9 | 2022 | 7 | |
| 10 | 2022 | 16 | |
| 11 | 2022 | 8 | |
| 12 | 2021 | 67 | |
| 13 | 2021 | 24 | |
| 14 | 2021 | 31 | |
| 15 | 2019 | 21 | |
| 16 | 2019 | 17 | |
| 17 | 2018 | 24 | |
| 18 | Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on | 2018 | 403 |
| 19 | 2017 | 4 | |
| 20 | 2014 | 242 |
About Jun J. Yang
Jun J. Yang is a scholar working on Public Health, Environmental and Occupational Health, Hematology and Pediatrics, Perinatology and Child Health, having authored 185 papers that have together received 7.0k indexed citations. Recurring topics across this work include Acute Lymphoblastic Leukemia research (95 papers), Childhood Cancer Survivors' Quality of Life (51 papers), Acute Myeloid Leukemia Research (23 papers), Epigenetics and DNA Methylation (16 papers), Immune Cell Function and Interaction (13 papers), Chronic Myeloid Leukemia Treatments (12 papers), RNA modifications and cancer (10 papers) and Biochemical and Molecular Research (9 papers). The work is most often cited by research in Hematology (1.3k citations), Public Health, Environmental and Occupational Health (3.0k citations) and Pediatrics, Perinatology and Child Health (1.9k citations). Jun J. Yang has collaborated with scholars based in United States, China and Singapore. Frequent co-authors include Ching‐Hon Pui, Mary V. Relling, William E. Evans, Philip S. Low, Deepa Bhojwani, Stefan Feske, Ji‐Xin Cheng, Kjeld Schmiegelow, Iontcho R. Vlahov and Stephen P. Hunger. Their work appears in journals such as Blood, Clinical Pharmacology & Therapeutics, Leukemia, Nature Communications and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.